Frank Westermann
Frank Westermann
Associate Professor of Tumor Biology and Personalized Medicine
Verified email at - Homepage
Cited by
Cited by
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
J Khan, JS Wei, M Ringner, LH Saal, M Ladanyi, F Westermann, ...
Nature medicine 7 (6), 673-679, 2001
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis
L Ma, J Young, H Prabhala, E Pan, P Mestdagh, D Muth, ...
Nature cell biology 12 (3), 247-256, 2010
The landscape of genomic alterations across childhood cancers
SN Gröbner, BC Worst, J Weischenfeldt, I Buchhalter, K Kleinheinz, ...
Nature 555 (7696), 321-327, 2018
A novel and universal method for microRNA RT-qPCR data normalization
P Mestdagh, P Van Vlierberghe, A De Weer, D Muth, F Westermann, ...
Genome biology 10, 1-10, 2009
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models
Nature biotechnology 28 (8), 827-838, 2010
Telomerase activation by genomic rearrangements in high-risk neuroblastoma
M Peifer, F Hertwig, F Roels, D Dreidax, M Gartlgruber, R Menon, ...
Nature 526 (7575), 700-704, 2015
Histone deacetylase 8 in neuroblastoma tumorigenesis
I Oehme, HE Deubzer, D Wegener, D Pickert, JP Linke, B Hero, ...
Clinical Cancer Research 15 (1), 91-99, 2009
Neuroblastoma: biology and molecular and chromosomal pathology
M Schwab, F Westermann, B Hero, F Berthold
The lancet oncology 4 (8), 472-480, 2003
Mutational dynamics between primary and relapse neuroblastomas
A Schramm, J Köster, Y Assenov, K Althoff, M Peifer, E Mahlow, ...
Nature genetics 47 (8), 872-877, 2015
Customized oligonucleotide microarray gene expression–based classification of neuroblastoma patients outperforms current clinical risk stratification
A Oberthuer, F Berthold, P Warnat, B Hero, Y Kahlert, R Spitz, K Ernestus, ...
Journal of clinical oncology 24 (31), 5070-5078, 2006
Next-generation personalised medicine for high-risk paediatric cancer patients–The INFORM pilot study
BC Worst, CM van Tilburg, GP Balasubramanian, P Fiesel, R Witt, ...
European journal of cancer 65, 91-101, 2016
Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas
F Westermann, D Muth, A Benner, T Bauer, KO Henrich, A Oberthuer, ...
Genome biology 9, 1-14, 2008
A mechanistic classification of clinical phenotypes in neuroblastoma
S Ackermann, M Cartolano, B Hero, A Welte, Y Kahlert, A Roderwieser, ...
Science 362 (6419), 1165-1170, 2018
Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia
P Nürnberg, H Thiele, D Chandler, W Höhne, ML Cunningham, H Ritter, ...
Nature genetics 28 (1), 37-41, 2001
Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma
JS Wei, BT Greer, F Westermann, SM Steinberg, CG Son, QR Chen, ...
Cancer research 64 (19), 6883-6891, 2004
Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma
H Kocak, S Ackermann, B Hero, Y Kahlert, A Oberthuer, D Juraeva, ...
Cell death & disease 4 (4), e586-e586, 2013
Genetic parameters of neuroblastomas
F Westermann, M Schwab
Cancer letters 184 (2), 127-147, 2002
FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma
M Remke, T Hielscher, A Korshunov, PA Northcott, S Bender, M Kool, ...
J Clin Oncol 29 (29), 3852-3861, 2011
Targeting MYCN-driven transcription by BET-bromodomain inhibition
A Henssen, K Althoff, A Odersky, A Beckers, R Koche, F Speleman, ...
Clinical Cancer Research 22 (10), 2470-2481, 2016
MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival
EA Afanasyeva, P Mestdagh, C Kumps, J Vandesompele, V Ehemann, ...
Cell Death & Differentiation 18 (6), 974-984, 2011
The system can't perform the operation now. Try again later.
Articles 1–20